The KEYNOTE-811 trial found that immunotherapy pembrolizumab combined with trastuzumab and chemotherapy increased the objective response rate of HER2-positive gastric cancer by 22.7%, and the incidence of adverse events is less [25]. Here, ERBB2 is linked to gastric cancer.